阿德福韦酯联合乙肝疫苗治疗慢性乙型肝炎疗效观察  

The Efficacy of Adefovir Dipivoxil Combined with Hepatitis B Vaccine Cured Chronic Hepatitis B

作　　者：吴新员[1] 黎志良[1] 周伶俐[1] 黄佳[1] 

机构地区：[1]湖北省咸宁市通城县人民医院内三科,咸宁437400

出　　处：《中国医药导刊》2010年第12期2102-2103,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察阿德福韦酯联合乙肝度苗治疗慢性乙型肝炎(CHB)的临床疗效和安全性。方法:随机选择我院2008年3月～2009年3月传染科病房或肝病门诊的97例慢性乙型肝炎患者并分成两组:两组患者均在一般保肝、抗炎对症治疗的基础上,观察组给予阿德福韦酯联合乙肝疫苗治疗;对照组仅给予阿德福韦酯抗病毒治疗,疗程均为12个月。疗程中观察症状改善情况并定期检测肝功、HBeAg、HBVDNA。结果:治疗6个月与12个月时,观察组的总有效率HBeAg阴转率、ALT复常率均高于对照组,差异有统计学意义(P<0.05),HBV-DNA阴转率也高于对照组,但两组比较,差异无统计学意义(P>0.05)。两组患者无一例发生不良反应。结论:阿德福韦酯联用乙肝疫苗治疗慢性乙型肝炎能有效控制病毒复制,改善肝功能,二者联用有一定协同作用,是治疗CHB的一种安全有效的方法,值得临床推广。Objective：To observe the efficacy and safety of adefuvir dipivoxil（ADV）for the treatment of chronic hepatitis B（CHB）. Methods：97 patients with chronic hepatitis B patients were divided into observation group and control group and two groups for general fiver protection Liver treatment,the observation group was treated with adefovir dipivoxil and Hepatitis B vaccine,while holy adefovir dipivoxil in other group for t 2 months.To compare the two groups after treatment in patients with major symptoms,liver function,HBV-DNA levels,hepatitis B virus serum markers change.Results：After 6 months and 12 months of the treatment,the observation group to improve symptoms,ALT normalization rate and the total effective rate was superior to adefovir dipivoxil alone control group（P〈0.05）,observation group,HBV-DNA negative conversion rate was higher, but the diference between the two groups compared with no significant（P〉0.05）.None of the two groups occurred in patients with adverse reactions.Conclusion：Adefovir dipivoxil combined with Hepatitis Bvaccine in treatment of CHB can effectively control viral replication,improve liver function,and it is a safe and elective method for treatment of chronic hepatitis B.It is worth to promote the application of clinica 1.

关 键 词：慢性乙型肝炎 阿德福韦酯 联合治疗 乙肝疫苗 临床疗效 

分 类 号：R512.62[医药卫生—内科学]